Erleada

Showing 5 posts of 5 posts found.

janssen_latest_logo_on_sign_closer

Janssen’s Erleada expanded in Europe to cover metastatic hormone-sensitive prostate cancer

January 29, 2020
Research and Development, Sales and Marketing Erleada, Europe, Janssen, pharma

Janssen’s Erleada (apalutamide) has secured expanded authorisation from the European Commission (EC), approving its label to include the treatment of …

janssen_latest_logo_on_sign_closer

FDA expands Janssen’s Erleada label to cover metastatic castration-sensitive prostate cancer

September 19, 2019
Sales and Marketing Cancer, Erleada, FDA, Janssen, pharma, prostate cancer

Janssen has announced that the FDA has expanded the label of its androgen receptor inhibitor Erleada (apalutamide) to include the …

janssen_latest_logo_on_sign_closer

Janssen’s Erleada combo smashes endpoints in advanced hormone-sensitive prostate cancer

June 3, 2019
Research and Development, Sales and Marketing ASCO 2019, Cancer, Erleada, Janssen, prostate cancer

Janssen joined the showing at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago to present new …

janssen_latest_logo_on_sign

Janssen’s Erleada meets primary endpoints in ongoing trial into metastatic castration-sensitive prostate cancer

January 31, 2019
Research and Development Cancer, Erleada, Janssen, pharma, prostate cancer

Janssen has revealed that its androgen receptor (AR) inhibitor Erleada (apalutamide), in combination with androgen deprivation therapy (ADT), has been …

jj

J&J’s apalutamide scores snap FDA approval in castration-resistant prostate cancer subgroup

February 15, 2018
Sales and Marketing Cancer, Erleada, FDA, J&J, JJ, Johsnon & Johnson, apalutamide, pharma, prostate cancer

Johnson & Johnson has announced that its androgen receptor inhibitor apalutamide, now branded as Erleada, has received approval from the …

Latest content